Aptamers 2015 encourages demonstration of R&D and laboratory supplies related to DNA/RNA oligonucleotide research and invites commercial sponsorship. You are invited to choose from a variety of highly-competitive sponsorship packages listed below. If your needs are not covered by the offered packages please contact us in the first instance and we shall do our best to develop a package to suit your requirements.
>Gold: Includes a speaker slot AND an exhibition stand
>Silver: Includes a speaker slot OR an exhibition stand
>Delegate Bags (max 2)
>Delegate Badges (max 2)
>Symposium Proceedings (max 2)
For a Booking Form and further information about packages and other promotional opportunities email on:
Terms & Conditions of Booking.
Aptamers 2015 Sponsors
Gold Sponsor and Exhibitor
Aptamer Solutions Ltd is a York based Biotechnology Company specialising in the custom selection of high-affinity and highly specific nucleic acid aptamers for use in the life sciences sector. Our proprietary automated high-throughput aptamer selection processes allow us to offer a flexible and competitive pricing structure for the development of RNA and DNA aptamers. In addition, we are about to launch a new complementary technology in the area of biomarker discovery.
Our proprietary aptamer based biomarker discovery platform and proprietary combinatorial libraries contain up to and over 1018 different molecules, this diversity and bespoke library design is fundamental to the success of the screening process. This technology enables us to greatly speed up the identification of novel biomarkers as well as diagnostics and/or therapeutic candidate molecules. This technology builds on one of the most powerful uses of aptamer technology, which is the ability for aptamers to be isolated against targets without any prior knowledge of the target.
Our aptamer-based proteomic technology identifies novel biomarkers within the cell surface (such as tumours, cell lines or stem cells) or in samples of biological fluids (such as, urine, plasma and saliva). The technology is versatile and can also be applied to viruses, bacteria, fungi or any other cell based materials or extracts. The discovery process is driven by identifying differences between sample population using enormous aptamer libraries. Samples are prepared based on broad classifications such as: disease vs normal; pre-metastatic vs. post metastatic cancers; pathogenic vs non-pathogenic fungi etc. The process is fast and efficient and identifies differences between ‘healthy’ and ‘diseased’ whilst simultaneously developing the affinity reagent. This cuts out many of the steps associated with traditional biomarker discovery processes.
The 2bind GmbH, Regensburg, Germany, provides biophysical analyses of molecular interactions. We work with worldwide customers from pharma, biotech as well as universities on the characterization of molecular interactions in terms of binding affinities, stoichiometries and binding energetics. Our semi-automated platform based on the MicroScale Thermophoresis technology (MST) allows us to offer cost-efficient, precise and fast analyses of molecular interactions. The integrated quality controls of the MST system enable us to easily identify sticking and aggregation effects and to directly improve measurement conditions ensuring high quality data. In addition to immobilization-free measurements in free solution, MST offers free choice of buffer, allowing close to native measurements in sera and lysates. Besides the low sample consumption our customers benefit from the broad application range of the MST. With our strong expertise in assay development, the company established standardized assays to analyze aptamer-target interactions in semi-high throughput for the aptamer developing industry and scientists. Further MST services includes competition assays, binding site mapping assays and binding assays that simultaneously test multiple binding partners. Hence, our services based on the MST technology are perfectly suitable for the identification, characterization and optimization of aptamer-target interactions.
Aptamers 2014 Sponsors